Gold prices edge lower; heading for weekly losses ahead of U.S.-Russia talks
Collplant Biotechnologies Ltd. (CLGN) stock has touched a 52-week low, reaching a price level of $2.14 USD, signaling a period of significant bearish momentum for the company. According to InvestingPro analysis, the stock’s RSI indicates oversold conditions, while analysts maintain a $14 price target, suggesting potential upside from current levels. This latest price point reflects a stark contrast to the stock’s performance over the past year, with Collplant ADR (NASDAQ:CLGN) witnessing a substantial 1-year change, plummeting by -58.6%. Investors are closely monitoring the stock as it navigates through a challenging market environment, with the 52-week low serving as a critical indicator of the company’s current valuation and investor sentiment. While the company faces near-term challenges, InvestingPro data reveals analysts expect sales growth and profitability this year. Discover 13 additional exclusive ProTips and access comprehensive Pro Research Reports covering what really matters about CLGN and 1,400+ other stocks through InvestingPro’s deep-dive analysis.
In other recent news, Collplant Biotechnologies faced a challenging Q4 2024, reporting earnings per share of -$0.34, which fell short of the forecasted -$0.275. Revenue also missed expectations, coming in at $164,000 compared to the anticipated $432,000, marking a significant year-over-year decline from $299,000 in Q4 2023. For the full year, the company reported a net loss of $16.6 million, or $1.45 per share, with total revenue dropping to $515,000 from $11 million in 2023. Despite these setbacks, the company received a $2 million payment from AbbVie (NYSE:ABBV) in February 2025, indicating progress in their partnership. Looking ahead, Collplant plans to expand its distribution channels for the Virgenix STR product in Europe and Asia and focus on optimizing its regenerative breast implants. The company maintains a stable cash position, expected to last through Q2 2026, as noted by CFO Eran Rotem. CEO Yihil Tal emphasized the company’s commitment to innovation and market expansion in regenerative medicine.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.